Company Overview
Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. The company provides inhaled formulations of oral medicines directly to the lungs. Its current pipeline is focused on treating pulmonary fibrosis. Its products include AP01 and AP02, inhaled formulations of pirfenidone and nintedanib for the treatment of progressive pulmonary fibrosis and idiopathic pulmonary fibrosis; and AP03, a fixed-dose combination of inhaled pirfenidone and nintedanib to deliver dual antifibrotic mechanisms. Avalyn Pharma Inc. was formerly known as Genoa Pharmaceuticals, Inc. and changed its name to Avalyn Pharma Inc. in July 2017. The company was incorporated in 2011 and is based in Boston, Massachusetts.
Why Investors Should Care
Generates a return on equity of 35.7%, reflecting efficient use of shareholder capital.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +27.57% |
| 6 Months: | - |
| 3 Months: | +34.07% |
| 1 Month: | +10.91% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- RSI (14)60.58 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 35.7%.
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | AVLN Avalyn Pharma Inc. R3KPHARMA | 37.62 | -16.15 | $1.67B | 0.00% | -67.73% | 35.70% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue | 0 | 0 |
| Cost of Revenue | - | - |
| Gross Profit | - | - |
| Operating Expenses | 18.72M | 27.91M |
| Operating Income | -18.72M | -27.91M |
| EBITDA | -17.49M | -26.71M |
| Interest Expense | 0 | 98.00K |
| Pretax Income | -17.50M | -26.87M |
| Tax Provision | - | - |
| Net Income | -17.50M | -26.87M |
| Diluted EPS | -0.42 | -0.64 |
| R&D Expense | 15.32M | 22.89M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Revenue | 0 | 0 |
| Cost of Revenue | - | - |
| Gross Profit | - | - |
| Operating Expenses | 57.12M | 91.29M |
| Operating Income | -57.12M | -91.29M |
| EBITDA | -57.09M | -91.25M |
| Interest Expense | - | - |
| Pretax Income | -49.74M | -85.20M |
| Tax Provision | - | - |
| Net Income | -49.74M | -85.20M |
| Diluted EPS | -1.19 | -2.04 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Total Assets | 124.52M | 148.88M |
| Current Assets | 114.39M | 143.56M |
| Cash & Equivalents | 23.95M | 52.31M |
| Inventory | - | - |
| Receivables | 591.00K | 537.00K |
| Total Liabilities | 299.04M | 387.54M |
| Current Liabilities | 8.74M | 14.09M |
| Long Term Debt | - | - |
| Total Debt | 0 | 1.67M |
| Total Equity | -174.52M | -238.66M |
| Shares Outstanding | 41.81M | 41.81M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Operating Cash Flow | -48.37M | -81.48M |
| Investing Cash Flow | -91.47M | 10.06M |
| Financing Cash Flow | 89.00K | 99.79M |
| Capital Expenditure | -95.00K | -344.00K |
| Free Cash Flow | -48.46M | -81.83M |
| Net Change in Cash | -139.75M | 28.36M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Gross Margin % | - | - |
| Operating Margin % | - | - |
| Net Margin % | - | - |
| ROE % | 28.5% | 35.7% |
| ROCE % | -49.3% | -67.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 13.16% | 5.84M | $183.93M |
| 2 | Novo Holdings A/S | 8.76% | 3.88M | $122.40M |
| 3 | SR One Capital Management, LP | 7.46% | 3.31M | $104.29M |
| 4 | Perceptive Advisors Llc | 6.03% | 2.68M | $84.33M |
| 5 | Montanova Capital LLC | 5.65% | 2.50M | $78.90M |
| 6 | NVP Associates, LLC | 5.12% | 2.27M | $71.50M |
| 7 | Wellington Management Group, LLP | 4.97% | 2.20M | $69.41M |
| 8 | Price (T.Rowe) Associates Inc | 3.91% | 1.74M | $54.69M |
| 9 | Catalio Capital Management, LP | 3.78% | 1.68M | $52.82M |
| 10 | T. Rowe Price Investment Management, Inc. | 3.62% | 1.60M | $50.52M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for AVLN
Morgan Stanley's New York healthcare event will include Avalyn Sept. 14 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxQQnYzSkFiQXZKY1NhRXB4cmlHdWVINkFkOWN2ZUdRU1o1OVR0UEVfcEpZcjh4ZjFiQmw5MzlfU2ExNUthbTlaUlpuRHpia2hEVzlSN3B0ZjV3N1BXSlZ0Q2ZNWEhPRWI5dUc2VDZVRzl0aFA3ZF8wSmJoS1lFWWpTbGJEbWxfSFRuV0VaUH…
People with lung scarring are willing to travel for trials, Avalyn survey finds - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxQVE01WjJsQXVPejllemg3MmpkOXlBc3dlZHpYYWs2ZUtxWm9Fd29uM0RRbWRtQ3RuRkNIZVlRZ3FOOFJnWHVMU1Q2ZjVoTDd6UTRPWEMwa1l6X2FzeDNKbVREdktsVWFkYjBfZFNBdFZtV29QTW9Oem1SMUZPTjhMbVZ6NUdkdkdsY1p0b3…
Avalyn Pharma Inc. (NASDAQ:AVLN) Given Average Rating of "Moderate Buy" by Brokerages - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMi3AFBVV95cUxNNUdYZzl6OTVXT05MT1FoVU9iUWVhS1lLa25MM0ctbWh2bGhScTJWUUJYNEE5LXhHWnVGYnhDVHZfaVk4aWZ5d1R2cXVtQXQtbWswVS1JX3k4SmVIay0wMnNBc0pXbzYzV2o4dEpQNTJ4LWt4RW8wNERRTTRPN19rNi1POHNENG1zd3NKUT…
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTFB5NXJBZWs2UW9nQmlONTA3NWtQeFVXdm1VcDYyRlJSbE1BSzNYQkpfV09JRURlN1hydDJicGVQbm5lXzJoZWcycTZldTY3czlM?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <fon…
Avalyn Pharma Inc. Common Stock (NASDAQ: AVLN) Stock Price, News & Analysis - kalkine.com.au
<a href="https://news.google.com/rss/articles/CBMiVkFVX3lxTFBzdE5iUm8wUXdGRm1kQlEyRURnQko5ekFtaVN4WGZKb0p3VUk4LUpEMEE2Z1VrbUN0NnRwMmdkQXdUYngxNHQ3UE53Ti10bXl2Wl8xbERR?oc=5" target="_blank">Avalyn Pharma Inc. Common Stock (NASDAQ: AVLN) Stoc…
Avalon Advanced Materials Stock Price Forecast. Should You Buy AVLNF? - StockInvest.us
<a href="https://news.google.com/rss/articles/CBMiSkFVX3lxTE5taVRBQTNmcFhRd09MMk12c2tXWEJNbWF3M0ZUeTQ1Nk41UEpSWXlUX0ZMdzlXb3F2c3IyOWxlTWhjR2p3cU12eUpB?oc=5" target="_blank">Avalon Advanced Materials Stock Price Forecast. Should You Buy AVLN…
AVLN — Frequently Asked Questions
What is the current share price of Avalyn Pharma Inc. (AVLN)?
As of 2026-09-19 21:16 PDT, Avalyn Pharma Inc. (AVLN) trades at $37.62 on NasdaqGS. Its 52-week range is $25.68 to $39.25.
What is the market capitalisation of AVLN?
Avalyn Pharma Inc. (AVLN) has a market capitalisation of $1.67B on NasdaqGS.
What is the P/E ratio of AVLN?
AVLN trades at a trailing price-to-earnings (P/E) ratio of -16.15. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 3.99.
What is the return on equity (ROE) of AVLN?
AVLN has a return on equity (ROE) of 35.70%. Its return on capital employed (ROCE) is -67.73%.
Is AVLN a good stock to buy?
This page provides a data-driven analysis of Avalyn Pharma Inc. (AVLN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.